PL210408B1 - Zastosowanie podstawionych cyjanopirolidyn do wytwarzania leku do modulowania hiperlipidemii - Google Patents
Zastosowanie podstawionych cyjanopirolidyn do wytwarzania leku do modulowania hiperlipidemiiInfo
- Publication number
- PL210408B1 PL210408B1 PL374016A PL37401603A PL210408B1 PL 210408 B1 PL210408 B1 PL 210408B1 PL 374016 A PL374016 A PL 374016A PL 37401603 A PL37401603 A PL 37401603A PL 210408 B1 PL210408 B1 PL 210408B1
- Authority
- PL
- Poland
- Prior art keywords
- compound
- formula
- hyperlipidemia
- cholesterol
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38522002P | 2002-06-03 | 2002-06-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL374016A1 PL374016A1 (en) | 2005-09-19 |
| PL210408B1 true PL210408B1 (pl) | 2012-01-31 |
Family
ID=29712145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL374016A PL210408B1 (pl) | 2002-06-03 | 2003-06-02 | Zastosowanie podstawionych cyjanopirolidyn do wytwarzania leku do modulowania hiperlipidemii |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20050176806A1 (enExample) |
| EP (1) | EP1513519B1 (enExample) |
| JP (2) | JP2005532338A (enExample) |
| KR (1) | KR20050012771A (enExample) |
| CN (2) | CN100402026C (enExample) |
| AT (1) | ATE422884T1 (enExample) |
| AU (2) | AU2003245903B2 (enExample) |
| BR (1) | BR0311535A (enExample) |
| CA (1) | CA2487297C (enExample) |
| CY (1) | CY1112800T1 (enExample) |
| DE (1) | DE60326232D1 (enExample) |
| DK (1) | DK1513519T3 (enExample) |
| EC (1) | ECSP045469A (enExample) |
| ES (1) | ES2321600T3 (enExample) |
| IL (1) | IL165181A (enExample) |
| MX (1) | MXPA04012149A (enExample) |
| NO (1) | NO333585B1 (enExample) |
| NZ (1) | NZ536832A (enExample) |
| PL (1) | PL210408B1 (enExample) |
| PT (1) | PT1513519E (enExample) |
| RU (1) | RU2362555C2 (enExample) |
| SG (1) | SG154333A1 (enExample) |
| SI (1) | SI1513519T1 (enExample) |
| WO (1) | WO2003101448A1 (enExample) |
| ZA (1) | ZA200409136B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| JP5122144B2 (ja) * | 2004-01-20 | 2013-01-16 | ノバルティス アーゲー | 直接圧縮製剤および方法 |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2006083214A1 (en) * | 2005-02-02 | 2006-08-10 | Astrazeneca Ab | Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor |
| MX2007011453A (es) | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| WO2008097535A2 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Method of treating atherosclerosis, dyslipidemias and related conditions |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| JP2013523819A (ja) | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| KR101298788B1 (ko) * | 2011-03-15 | 2013-08-22 | 보령제약 주식회사 | 안정성이 개선된 복합제제 |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| EA202192328A1 (ru) * | 2019-03-22 | 2022-02-21 | Раш Юниверсити Медикал Сентер | Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2572399B1 (fr) * | 1984-10-31 | 1987-01-16 | Panmedica Sa | Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant |
| TW222626B (enExample) * | 1991-07-22 | 1994-04-21 | Pfizer | |
| DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| EP1052994A2 (en) * | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
| DE19828114A1 (de) * | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828113A1 (de) * | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| CN1332726A (zh) * | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| JP4232332B2 (ja) * | 1999-11-10 | 2009-03-04 | 末藏 岩田 | タンク付電動床磨機用ブラシ台 |
| ATE385421T1 (de) * | 2000-01-21 | 2008-02-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
| JP2005507261A (ja) * | 2001-10-31 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法 |
| PE20040291A1 (es) * | 2002-03-22 | 2004-07-02 | Novartis Ag | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA |
| GB0212412D0 (en) * | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| WO2005117861A1 (en) * | 2004-06-04 | 2005-12-15 | Novartis Ag | Use of organic compounds |
| AU2006292377B2 (en) * | 2005-09-20 | 2011-03-03 | Emisphere Technologies, Inc. | Use of a DPP-IV inhibitor to reduce hypoglycemic events |
-
2003
- 2003-06-02 CN CNB038128446A patent/CN100402026C/zh not_active Expired - Fee Related
- 2003-06-02 RU RU2004139029/14A patent/RU2362555C2/ru not_active IP Right Cessation
- 2003-06-02 MX MXPA04012149A patent/MXPA04012149A/es active IP Right Grant
- 2003-06-02 ES ES03737984T patent/ES2321600T3/es not_active Expired - Lifetime
- 2003-06-02 CA CA2487297A patent/CA2487297C/en not_active Expired - Fee Related
- 2003-06-02 DE DE60326232T patent/DE60326232D1/de not_active Expired - Lifetime
- 2003-06-02 BR BR0311535-6A patent/BR0311535A/pt not_active IP Right Cessation
- 2003-06-02 EP EP03737984A patent/EP1513519B1/en not_active Expired - Lifetime
- 2003-06-02 PT PT03737984T patent/PT1513519E/pt unknown
- 2003-06-02 SI SI200331571T patent/SI1513519T1/sl unknown
- 2003-06-02 KR KR10-2004-7019595A patent/KR20050012771A/ko not_active Ceased
- 2003-06-02 AT AT03737984T patent/ATE422884T1/de active
- 2003-06-02 PL PL374016A patent/PL210408B1/pl not_active IP Right Cessation
- 2003-06-02 AU AU2003245903A patent/AU2003245903B2/en not_active Ceased
- 2003-06-02 WO PCT/EP2003/005762 patent/WO2003101448A1/en not_active Ceased
- 2003-06-02 CN CNA2008100965659A patent/CN101273987A/zh active Pending
- 2003-06-02 SG SG200608456-0A patent/SG154333A1/en unknown
- 2003-06-02 JP JP2004508806A patent/JP2005532338A/ja not_active Withdrawn
- 2003-06-02 DK DK03737984T patent/DK1513519T3/da active
- 2003-06-02 NZ NZ536832A patent/NZ536832A/en not_active IP Right Cessation
- 2003-06-02 US US10/516,633 patent/US20050176806A1/en not_active Abandoned
-
2004
- 2004-11-11 ZA ZA2004/09136A patent/ZA200409136B/en unknown
- 2004-11-11 IL IL165181A patent/IL165181A/en not_active IP Right Cessation
- 2004-12-01 EC EC2004005469A patent/ECSP045469A/es unknown
- 2004-12-14 NO NO20045452A patent/NO333585B1/no not_active IP Right Cessation
-
2006
- 2006-11-30 AU AU2006246483A patent/AU2006246483B9/en not_active Ceased
-
2009
- 2009-05-11 CY CY20091100499T patent/CY1112800T1/el unknown
-
2010
- 2010-04-05 JP JP2010087181A patent/JP2010155866A/ja active Pending
-
2011
- 2011-09-26 US US13/245,226 patent/US20120014907A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120014907A1 (en) | Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | |
| EP1572196B1 (en) | Combination of a dpp-iv inhibitor and a ppar-alpha compound | |
| EP1741447B1 (en) | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | |
| JP2005532338A5 (enExample) | ||
| JP6940411B2 (ja) | Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法 | |
| Keane et al. | Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? | |
| WO1998001119A2 (en) | Pharmaceutical compositions comprising simvastatin | |
| RS52825B (sr) | Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata | |
| MX2010013664A (es) | Derivados de piperidinilo como modulador de la actividad de los receptores de quimiocinas. | |
| SK11112001A3 (sk) | Použitie prostriedku znižujúceho cholesterol | |
| JP2021535136A (ja) | 心血管疾患及び関連する状態を有する患者を処置するための併用薬製剤 | |
| JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
| HK1074794B (en) | The use of substituted cyanopyrrolidines for treating hyperlipidemia | |
| NZ548902A (en) | The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases | |
| Shimpi et al. | Bempedoic acid a novel drug used for the treatment of Hyperlipidaemia: A Review | |
| MXPA01012644A (es) | Combinaciones antilipemicas que comprenden inhibidores de hmg-coa reductasa y carnitina. | |
| CA2494801A1 (en) | Medicinal composition containing hmg-coa reductase inhibitor | |
| US20090275551A1 (en) | Fluvastatin for the treatment of patients with a history of muscle related side effects with other statins | |
| HK1085377B (en) | Combination of a dpp-iv inhibitor and a ppar-alpha compound | |
| EP1946779A1 (en) | Combination of substituted pyrazolines and agent for treating dyslipidemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification | ||
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20140602 |